Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ITV-1 + IPF Immune
- Development stage
- Unknown
- Lead developer
- Virogentics
- Modality
- Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Subcutaneous
01
Overview
**ITV-1 + IPF Immune** is a combination immunotherapy comprising ITV-1, a patented suspension of inactivated pepsin fraction (IPF) that modulates the immune system by targeting gp41 on HIV, and IPF Immune, a nutraceutical product marketed as an immunomodulator. Developed by Virogentics (a subsidiary of Enzolytics, Inc.), with historical roots in Immunotech Laboratories, this duo is primarily indicated for HIV/AIDS treatment, where ITV-1 has shown efficacy in prior clinical testing and is advancing to Phase 3 trials in Bulgaria targeting 60 patients, expected to start late 2023/early 2024 under EMA guidance. IPF Immune supports broader immune applications, including potential adjunct use in cirrhosis, post-radiation/chemotherapy recovery, type 2 diabetes, herpes, COVID, influenza, and autoimmune diseases, with ongoing exploration in these areas.[1][2][4][5][6]
- Other names
- Immune Therapeutic Vaccine-1IPF-ITV PhasesImmunH + [2]
02
Targets
gp41 (Human immunodeficiency virus type 1 glycoprotein 41)
Beyond the preview
Go deeper on ITV-1 + IPF Immune.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ITV-1 + IPF Immune.